New Breast Cancer Treatment Now Available in Thailand
Women facing challenges with breast cancer in Thailand can now access a groundbreaking new therapy—NERLYNX (neratinib). This treatment introduction marks a significant milestone, offering hope and new possibilities to those diagnosed with breast cancer.
About NERLYNX
NERLYNX is a revolutionary oral medication approved by the Thai FDA for treating early-stage HER2+ breast cancer. This drug is intended for women who have recently completed trastuzumab-based therapy. Women diagnosed with advanced or metastatic HER2+ breast cancer can also benefit from NERLYNX when it is combined with capecitabine, illustrating its dual capability as both a single agent and in therapeutic combinations.
The Importance of Targeted Treatments
HER2+ breast cancer accounts for approximately 15-25% of all breast cancer cases. Patients diagnosed with HER2+ types are faced with daunting odds, including a higher likelihood of disease recurrence and metastatic progression. Statistics reveal that as many as 26% of these patients experience a return of the disease after receiving initial treatment. NERLYNX has been shown to significantly decrease the chance of recurrence, particularly among those who are also hormone-receptor positive (HR+) and begin treatment shortly after completing trastuzumab.
Key Efficacy Findings
Clinical studies indicate that NERLYNX, especially when administered early, can reduce the five-year recurrence risk by as much as 42% for patients with early breast cancer. Moreover, for women dealing with advanced HER2+ breast cancer, combining NERLYNX with capecitabine resulted in extended progression-free survival by an average of 2.2 months compared to other treatment options.
Real Impact on Patients
Dr. Bhuvana Ramaswamy, a leading medical expert in Southeast Asia, emphasizes the importance of introducing NERLYNX in Thailand. She notes that over 20,000 new cases of breast cancer are diagnosed in the country annually, creating a pressing need for effective treatment options that can truly make a difference.
Commitment to Patient Care
Specialised Therapeutics, the independent pharmaceutical firm promoting NERLYNX in Thailand, showcases its dedication to addressing the local patient needs by launching this innovative therapy. Carolo Montagner, CEO of Specialised Therapeutics, expressed his excitement about making this important treatment available—an option previously not accessible to Thai women.
Broader Context of Breast Cancer in Thailand
Breast cancer remains a top health concern among Thai women and poses a serious challenge to healthcare systems. The annual incidence of breast cancer has alarmingly doubled in the past two decades, with breast cancer comprising a significant portion of all cancer diagnoses in women. With the increasing rates of breast cancer cases, NERLYNX arrives at a crucial time, providing much-needed support in the continuum of care for these patients.
Concluding Thoughts
The availability of NERLYNX signifies a leap forward in the treatment landscape for breast cancer in Thailand. With its introduction, eligible patients now have an enhanced opportunity to improve health outcomes and potentially reduce the harsh realities linked to breast cancer recurrence. The medical community looks forward to witnessing the profound impacts NERLYNX will have on patient recovery and quality of life moving forward.
Frequently Asked Questions
What is NERLYNX?
NERLYNX (neratinib) is a targeted therapy for HER2+ breast cancer, approved for early-stage treatment and advanced diseases.
How does NERLYNX work?
NERLYNX works as a tyrosine kinase inhibitor, blocking signals that promote cancer cell growth and multiplication.
Who can benefit from NERLYNX?
Women diagnosed with HER2+ breast cancer, both early-stage and advanced, can benefit from NERLYNX therapies.
How has NERLYNX impacted patient outcomes?
Studies show that NERLYNX can significantly reduce recurrence risk and improve disease-free survival rates in eligible patients.
What is the role of Specialised Therapeutics in Thailand?
Specialised Therapeutics is the company responsible for making NERLYNX available in Thailand, aiming to enhance treatment options and patient care.
